Before Invest
ELI LILLY & Co logo

ELI LILLY & Co

LLY
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Unlock 39 quarters
Statement
Period
Annual Quarterly
Order
Format
% Change
Rows
USD ($)
$ in Millions, shares in Millions		Jun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jun 30, 2023Mar 31, 2023Sep 30, 2022Jun 30, 2022Mar 31, 2022Sep 30, 2021Jun 30, 2021Mar 31, 2021Sep 30, 2020Jun 30, 2020Mar 31, 2020Sep 30, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jun 30, 2018Mar 31, 2018Sep 30, 2017Jun 30, 2017Mar 31, 2017Sep 30, 2016Jun 30, 2016Mar 31, 2016Sep 30, 2015Jun 30, 2015Mar 31, 2015Sep 30, 2014Jun 30, 2014Mar 31, 2014Sep 30, 2013Jun 30, 2013Mar 31, 2013Sep 30, 2012Jun 30, 2012Mar 31, 2012Sep 30, 2011Jun 30, 2011Mar 31, 2011Sep 30, 2010Mar 31, 2010Sep 30, 2009Jun 30, 2009
Net product sales
-
-
-
-
-
-
-
-
-
-
-
-
Collaboration and other revenue
-
-
-
-
-
-
-
-
-
-
-
-
Revenue
22,974
19,799
17,601
15,558
12,729
11,439
11,303
8,768
9,499
8,312
6,960
6,942
Costs, expenses, and other:
                                                   
Cost of sales
3,268
3,577
3,008
2,448
2,224
2,171
2,170
1,674
1,860
1,807
1,627
1,579
Research and development
3,819
3,510
3,466
3,336
2,734
2,734
2,711
2,523
2,409
2,357
1,985
1,803
Marketing, selling, and administrative
3,430
2,934
2,741
2,753
2,469
2,100
2,117
1,952
1,804
1,925
1,749
1,614
Acquired in-process research and development
2,776
584
656
154
1,572
2,826
154
111
2,975
97
105
-
Acquired in-process research and development and development milestones (Note 3)
-
-
-
-
-
-
-
-
-
-
-
62
Asset impairment, restructuring, and other special charges
703
279
365
0
35
82
435
-
0
-
-
207
Other–net, (income) expense
269
(65)
(133)
(91)
(239)
62
(198)
27
(23)
(37)
36
(111)
Costs, expenses, and other
13,727
10,949
10,368
8,781
9,272
9,851
7,786
6,232
9,071
6,223
5,430
5,376
Income before income taxes
9,247
8,850
7,232
6,776
3,456
1,588
3,517
2,536
427
2,089
1,530
1,566
Income taxes
2,152
1,454
1,650
1,116
697
618
550
293
485
326
185
114
Net income from continuing operations
-
-
-
-
-
-
-
-
-
-
-
-
Net income from discontinued operations (Note 5)
-
-
-
-
-
-
-
-
-
-
-
-
Net income
$ 7,095
$ 7,396
$ 5,583
$ 5,661
$ 2,759
$ 970
$ 2,967
$ 2,243
$ (57)
$ 1,763
$ 1,345
$ 1,452
Earnings per share:
                                                   
Earnings from continuing operations - basic (usd per share)
-
-
-
-
-
-
-
-
-
-
-
-
Earnings from discontinued operations - basic (usd per share)
-
-
-
-
-
-
-
-
-
-
-
-
Basic (in dollars per share)
7.95
8.27
6.22
6.3
3.07
1.08
3.29
2.49
(0.06)
1.96
1.49
1.61
Earnings from continuing operations - diluted (usd per share)
-
-
-
-
-
-
-
-
-
-
-
-
Earnings from discontinued operations - diluted (usd per share)
-
-
-
-
-
-
-
-
-
-
-
-
Diluted (in dollars per share)
7.94
8.26
6.21
6.29
3.06
1.07
3.28
2.48
(0.06)
1.95
1.49
1.61
Shares used in calculation of earnings per share:
                                                   
Basic (in shares)
892.4
894.5
896.9
897.9
898.7
901
900.9
900.8
899.8
899.7
901
900.7
Diluted (in shares)
893.7
895.9
898.8
899.8
900.6
905
904.2
903.8
899.8
902.7
903.3
903.8
Earnings per share - basic and diluted
-
-
-
-
-
-
-
-
-
-
-
-
Dividends paid per share (usd per share)
-
-
-
-
-
-
-
-
-
-
-
-